Measuring particle size distribution during the grinding process

A further step toward a stable measurement method for nanoparticles used in industry

26-Jul-2024 - How pharmaceuticals act, how efficient catalysts are and how effective and accurate printing inks function all depend on the size of the nanoparticles they contain. However, there are as of yet no methods for monitoring the particle size distribution during grinding processes. In the EU-funded ...

Evotec enters a drug discovery collaboration with Janssen

Milestones up to approximately € 210 m per project

14-Jun-2022 - Evotec SE announced that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Evotec’s innovative TargetAlloMod platforms will be evaluated to discover first-in-class novel mode of action ...

New insights could result in changes to the therapeutic strategy to combat Alzheimer’s

​System developed for this research that could reduce a number of animal tests.

28-May-2015 - A typical characteristic of the brain of an Alzheimer sufferer is the presence of insoluble Tau protein aggregates. Scientists at VIB, KU Leuven and Janssen Pharmaceutica have demonstrated that the distribution of these aggregates through the brain is facilitated by synaptic connections between ...

Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration

20-May-2015 - Proteros biostructures GmbH announced it had achieved an important milestone in a lead discovery collaboration with Janssen Pharmaceutica NV triggering an undisclosed payment to Proteros.Proteros has collaborated with Janssen for over a decade supporting numerous projects across all therapeutic ...

Philips enters into collaboration with Janssen to develop new handheld blood test

27-Mar-2015 - Royal Philips announced that it has entered into a multi-year development agreement with Janssen Pharmaceutica N.V.. The collaboration aims to develop a new handheld blood test to provide doctors with a novel tool to improve the care of patients with neuropsychiatric disorders.The collaboration ...

Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex

07-Nov-2012 - Medivir AB announced plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s protease inhibitor simeprevir and Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Janssen will conduct a ...

Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis

28-Aug-2012 - Janssen Biologics announced it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK). Sirukumab is a human anti-interleukin (IL)-6 monoclonal antibody being studied for the treatment of adults with moderately to severely ...

Public-private collaboration launches to tackle antibiotic research

New €224m (£180m) funding to enable development of antibiotics for bacterial infections and drive unprecedented information sharing

29-May-2012 - GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barriers to ...

Galapagos delivers candidate drug in its alliance with Janssen Pharmaceutica, NV and receives milestone payment

22-Mar-2012 - Galapagos NV announced that it has identified a pre-clinical compound in its alliance with Janssen Pharmaceutica NV. This achievement triggered a milestone payment of €6.6 million to Galapagos. The pre-clinical candidate was developed by Galapagos against a novel target discovered with ...

Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global Agreement

12-Jan-2012 - Janssen Research & Development, a division of Janssen Pharmaceutica NV and Proteros biostructures GmbH announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services.Under the agreement Janssen ...